Research And Markets Research And Markets

Therapeutic and Pharmaceutical Opportunities for Osteoporosis and Atherosclerosis

  • ID: 19801
  • March 2003
  • Lead Discovery
1 of 2

An estimated 10 million Americans over the age of 50 years old suffer from osteoporosis and a further 32.9 million have low bone mass, placing them at an increased risk for developing this condition. Associated with an increased risk of fractures which are both clinically problematic and costly to healthcare systems the development of new osteoporosis treatments offers immense opportunities to the pharmaceutical industry. The global osteoporosis therapies market, including estrogen replacement therapy drugs was estimated at $5.5 billion in 2001 and projected to double by 2008 in the face of population aging, decreased bone quality and increased awareness of osteoporosis.

Once dominated by hormone replacement therapies (HRTs), the field of osteoporosis has undergone three major changes since the mid-1990's. First, the bisphosphonate Fosamax was launched in 1995. Since this launch the bisphosphonates have become the most effective means of limiting bone loss. Then, in January 1998 Eli Lilly launched Evista (raloxifene), the first selective estrogen receptor modulator and as a result the concept of combining the beneficial effects of estrogen antagonism (ie anti-cancer activity) READ MORE >

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown